Actually, complete abrogation of EGFR N-glycosylation by tunicamycin led to increased susceptibility of EGFR to the tyrosine kinase (TK) inhibitor erlotinib, a frequently utilized drug to downregulate EGFR activation supporting constitutive proliferation of non-small cell lung cancer (49). This evidence concerns the gene TKT and non-small cell lung carcinoma.